πŸ”₯πŸ” BizChicken πŸ”πŸ”₯

Companies Similar to C4 Therapeutics, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

CytomX Therapeutics, Inc.

CytomX Therapeutics, Inc. logo
Market Cap: Low
Employees: Low

Probody technology platform

Cytom X Therapeutics, Inc. is an oncology-focused biopharmaceutical company that develops antibody therapeutics based on its Probody technology platform for treating cancer. Its product candidates include CX-2009, CX-2029, BMS-986249, BMS-986288, CX-2043, and CX-904, targeting various cancers and currently in clinical trials.

Tags: antibody therapeutics, biopharmaceuticals, cancer treatment, clinical trials, oncology

Symbol: CTMX

Recent Price: $1.02

Industry: Biotechnology

CEO: Dr. Sean A. McCarthy DPHIL

Sector: Healthcare

Employees: 120

Address: 151 Oyster Point Boulevard, South San Francisco, CA 94080

Phone: 650 515 3185

Last updated: 2024-12-31

Applied Therapeutics, Inc.

Applied Therapeutics, Inc. logo
Market Cap: Medium
Employees: Lowest

AT-007

Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products targeting cardiovascular disease, galactosemia, and diabetic complications. Key products include AT-007 and AT-001.

Tags: biopharmaceutical, cardiovascular disease, clinical trials, diabetic complications, galactosemia

Symbol: APLT

Recent Price: $0.81

Industry: Biotechnology

CEO: Dr. Shoshana Shendelman Ph.D.

Sector: Healthcare

Employees: 31

Address: 545 Fifth Avenue, New York, NY 10017

Phone: 212 220 9226

Leadership

  • Shoshana Shendelman, Chair, Board of Directors
  • Riccardo Perfetti, Chief Medical Officer
  • Les Funtleyder,
  • Dale Hooks, Chief Commercial Officer
  • Constantine Chinoporos, Chief Business Officer / Chief Operating Officer
  • Joel Marcus,
  • Jay Skyler,
  • Stacy Kanter,
  • Teena Lerner,
  • Donald Landry M.D., Ph.D., Chair, Scientific Advisory Board
  • Roy Freeman M.D.,
  • Roxana Mehran M.D.,
  • Lawrence Steinman M.D.,
  • Gregg Stone M.D.,
  • Donald d'Amico M.D.,
  • Donald Landry, Chair, Scientific Advisory Board
  • Roy Freeman,
  • Roxana Mehran,
  • Lawrence Steinman,
  • Gregg Stone,
  • Donald d'Amico,

Last updated: 2024-12-31

Candel Therapeutics, Inc.

Candel Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

CAN-2409, CAN-3110

Candel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing immunotherapies for cancer patients, with products like CAN-2409 and CAN-3110 in various clinical trial phases.

Tags: biopharmaceutical, cancer treatment, clinical trials, immunotherapies

Symbol: CADL

Recent Price: $7.95

Industry: Biotechnology

CEO: Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.

Sector: Healthcare

Employees: 42

Address: 117 Kendrick Street, Needham, MA 02494

Phone: 617 916 5445

Last updated: 2024-12-31

Cyclerion Therapeutics, Inc.

Cyclerion Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

CY6463

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing medicines for serious CNS diseases, with products like CY6463 for mitochondrial encephalomyopathy and Alzheimer's disease.

Tags: CNS diseases, CY6463, biopharmaceutical, clinical-stage, therapy development

Symbol: CYCN

Recent Price: $3.45

Industry: Biotechnology

CEO: Dr. Regina Graul Ph.D.

Sector: Healthcare

Employees: 1

Address: 245 First Street, Cambridge, MA 02142

Phone: 857 327 8778

Last updated: 2024-12-31

Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc. logo
Market Cap: Low
Employees: Low

losmapimod and FTX-6058

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing products to improve the lives of patients with genetically defined diseases in areas of high unmet medical need in the United States.

Tags: FTX-6058, biopharmaceutical, clinical-stage, facioscapulohumeral muscular dystrophy, genetically defined diseases, hemoglobinopathies, losmapimod, sickle cell disease

Symbol: FULC

Recent Price: $4.68

Industry: Biotechnology

CEO: Mr. Alexander C. Sapir

Sector: Healthcare

Employees: 76

Address: 26 Landsdowne Street, Cambridge, MA 02139

Phone: 617 651 8851

Last updated: 2024-12-31

Fate Therapeutics, Inc.

Fate Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

programmed cellular immunotherapies

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its development programs include various NK- and T-cell immuno-oncology therapies targeting different cancers.

Tags: NK cells, T-cells, biopharmaceutical, cancer treatment, clinical-stage, immunotherapy

Symbol: FATE

Recent Price: $1.62

Industry: Biotechnology

CEO: Mr. J. Scott Wolchko

Sector: Healthcare

Employees: 181

Address: 12278 Scripps Summit Drive, San Diego, CA 92131

Phone: 858 875 1800

Leadership

  • William Rastetter, Ph.D., Chairman
  • John Mendlein, Ph.D., J.D., Vice Chairman
  • Dr. Shefali Agarwal, Board Member
  • Timothy P. Coughlin, Board Member
  • Robert S. Epstein, M.D., Board Member
  • Karin Jooss, Ph.D., Board Member
  • Michael Lee, Board Member
  • Neely Mozaffarian, M.D., Ph.D., FACR, Board Member
  • Yuan Xu, Ph.D., Board Member
  • Scott Wolchko, President & CEO

Last updated: 2024-12-31

Oncternal Therapeutics, Inc.

Oncternal Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

zilovertamab, ONCT-216, ONCT-808, ONCT-534

Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in oncology therapies for cancers with significant unmet medical needs, featuring a pipeline that includes the monoclonal antibody zilovertamab and various other targeted treatments.

Tags: CAR-T, ROR1, antibody, biopharmaceutical, cancer therapy, clinical-stage, oncology

Symbol: ONCT

Recent Price: $0.53

Industry: Biotechnology

CEO: Dr. James B. Breitmeyer M.D., Ph.D.

Sector: Healthcare

Employees: 27

Address: 12230 El Camino Real, San Diego, CA 92130

Phone: 858 434 1113

Last updated: 2024-12-31

C4 Therapeutics, Inc.

C4 Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

CFT7455

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Their lead product candidate, CFT7455, targets multiple myeloma and non-Hodgkin lymphomas.

Tags: biopharmaceutical, cancer treatment, clinical-stage, neurodegenerative diseases, protein degradation, therapeutics

Symbol: CCCC

Recent Price: $3.64

Industry: Biotechnology

CEO: Mr. Andrew J. Hirsch M.B.A.

Sector: Healthcare

Employees: 145

Address: 490 Arsenal Way, Watertown, MA 02472

Phone: 617 231 0700

Leadership

  • Kendra Adams, Chief Financial Officer
  • Scott Boyle, Ph.D., Chief Business Officer
  • Stew Fisher, Ph.D., Chief Scientific Officer
  • Len Reyno, M.D., Chief Medical Officer
  • Jolie Siegel, Chief Legal Officer
  • Kelly Schick, Chief People Officer
  • Mary Christian, Pharm. D., Senior Vice President, Regulatory
  • Mayra Reyes-Armour, Ph.D., Senior Vice President, Technical Operations, Quality and Facilities
  • Ron Cooper, Chairman
  • Ken Anderson, M.D., Director
  • Laura Bessen, M.D., Director
  • Bruce Downey, Director
  • Stephen Fawell, Ph.D., Director
  • Donna Grogan, M.D., Director
  • Andrew Hirsch, President and Chief Executive Officer, Director
  • Owen Hughes, Director
  • Utpal Koppikar, Director
  • Marc Cohen, In MemoriamCo-Founder & Executive Chairman Emeritus

Last updated: 2024-12-31

Cognition Therapeutics, Inc.

Cognition Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

CT1812

Cognition Therapeutics is a clinical-stage biopharmaceutical company specializing in small molecule therapeutics for age-related degenerative diseases and central nervous system disorders. Its lead product, CT1812, is designed to treat Alzheimer's disease and dementia with Lewy bodies.

Tags: Alzheimer's disease, biopharmaceutical, central nervous system, retina disorders, small molecule therapeutics

Symbol: CGTX

Recent Price: $0.75

Industry: Biotechnology

CEO: Ms. Lisa Ricciardi

Sector: Healthcare

Employees: 25

Address: 2500 Westchester Avenue, Purchase, NY 10577

Phone: 412 481 2210

Leadership

  • Lisa Ricciardi, Chief Executive Officer​
  • Anthony C. Caggiano, M.D., Ph.D., Chief Medical Officer, Head of R&D
  • John Doyle, Chief Financial Officer
  • Anita Cornet, Head of Quality
  • Theresa Devins, DrPH, Vice President, Clinical Operations
  • Mary Hamby, Ph.D., Vice President, Research
  • Bobby Horn, Corporate Controller
  • Jennifer Iaci, Vice President, Development Operations
  • Steven A. Weissman, Ph.D., Vice President and Head of CMC
  • Jack A. Khattar, CEO
  • Aaron Fletcher, Ph.D.,
  • Brett P. Monia, Ph.D., CEO
  • Ellen B. Richstone,
  • Peggy Wallace,

Last updated: 2024-12-31

Checkpoint Therapeutics, Inc.

Checkpoint Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

Cosibelimab

Checkpoint Therapeutics, Inc. is a clinical-stage immunotherapy and targeted oncology company focused on acquiring, developing, and commercializing novel treatments for solid tumor cancers. Their lead product candidates include Cosibelimab, a fully-human monoclonal antibody, and other treatments for various cancer targets.

Tags: Antibody, Cancer Treatment, Cosibelimab, EGFR Inhibitor, Immunotherapy, Oncology

Symbol: CKPT

Recent Price: $3.35

Industry: Biotechnology

CEO: Mr. James F. Oliviero III, C.F.A.

Sector: Healthcare

Employees: 23

Address: 95 Sawyer Road, Waltham, MA 02453

Phone: 781 652 4500

Last updated: 2024-12-31

Compass Therapeutics, Inc.

Compass Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

CTX-009, CTX-471, CTX-8371

Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing antibody-based therapeutics to treat various human diseases. Their clinical stage products include investigational bispecific antibodies like CTX-009 and monoclonal antibodies such as CTX-471.

Tags: CTX-009, CTX-471, CTX-8371, antibody therapeutics, biopharmaceutical, clinical stage, oncology

Symbol: CMPX

Recent Price: $1.48

Industry: Biotechnology

CEO: Dr. Thomas J. Schuetz M.D., Ph.D.

Sector: Healthcare

Employees: 32

Address: 80 Guest Street, Boston, MA 02135

Phone: 617 500 8099

Last updated: 2024-12-31

Cogent Biosciences, Inc.

Cogent Biosciences, Inc. logo
Market Cap: Medium
Employees: Low

CGT9486

Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases, with lead product candidate CGT9486 targeting mutations driving systemic mastocytosis and advanced gastrointestinal stromal tumors.

Tags: biotechnology, genetically defined diseases, precision therapies, tyrosine kinase inhibitor

Symbol: COGT

Recent Price: $7.67

Industry: Biotechnology

CEO: Mr. Andrew R. Robbins M.B.A.

Sector: Healthcare

Employees: 164

Address: 200 Cambridge Park Drive, Cambridge, MA 02140

Phone: 617 945 5576

Last updated: 2024-12-31

4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

4D-125, 4D-110, 4D-310, 4D-150, 4D-710

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company developing product candidates using adeno-associated virus vectors, focusing on ophthalmology, cardiology, and pulmonology.

Tags: biotechnology, cardiology, gene therapy, ophthalmology, pulmonology

Symbol: FDMT

Recent Price: $5.30

Industry: Biotechnology

CEO: Dr. David H. Kirn M.D.

Sector: Healthcare

Employees: 201

Address: 5858 Horton Street, EmeryVille, CA 94608

Phone: 510 505 2680

Last updated: 2024-12-31

Indaptus Therapeutics, Inc.

Indaptus Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Decoy20

Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company focusing on the development of anti-cancer and anti-viral immunotherapy products, with its lead clinical candidate, Decoy20, targeting lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as viral infections.

Tags: Decoy20, anti-cancer, anti-viral, biotechnology, immunotherapy

Symbol: INDP

Recent Price: $0.87

Industry: Biotechnology

CEO: Mr. Jeffrey A. Meckler

Sector: Healthcare

Employees: 7

Address: 3 Columbus Circle, New York, NY 10019

Phone: 347 480 9760

Last updated: 2024-12-31

Century Therapeutics, Inc.

Century Therapeutics, Inc. logo
Market Cap: Low
Employees: Low

CNTY-101

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies.

Tags: CAR-i NK, CAR-i T, allogeneic, biotechnology, cell therapy, hematological malignancies, iPSC, solid tumors

Symbol: IPSC

Recent Price: $1.00

Industry: Biotechnology

CEO: Mr. Brent Pfeiffenberger M.B.A., Pharm.D.

Sector: Healthcare

Employees: 152

Address: 3675 Market Street, Philadelphia, PA 19104

Phone: 267 817 5790

Last updated: 2024-12-31

Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc. logo
Market Cap: High
Employees: Low

novel small molecule therapeutics

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system.

Tags: IRAK4 program, autoimmune diseases, biopharmaceutical, immunology, inflammation, oncology, protein degradation, therapeutics

Symbol: KYMR

Recent Price: $39.32

Industry: Biotechnology

CEO: Dr. Nello Mainolfi M.D., Ph.D.

Sector: Healthcare

Employees: 184

Address: 200 Arsenal Yards Boulevard, Watertown, MA 02472

Phone: 857 285 5300

Leadership

  • Nello Mainolfi, Ph.D., Founder, President & CEO
  • Jeremy Chadwick, Ph.D., Chief Operating Officer
  • Ellen Chiniara, JD, Chief Legal Officer and Corporate Secretary
  • Jared Gollob, MD, Chief Medical Officer
  • Bruce Jacobs, CFA, MBA, Chief Financial Officer
  • Karen Weisbach, Head of People and Culture
  • Juliet Williams, Ph.D., Head of Research
  • Bruce Booth, DPhil, Chairman and Co-Founder
  • Felix J. Baker, PhD, Lead Independent Director
  • Jeff Albers, JD, MBA,
  • Pamela Esposito, PhD,
  • Gorjan Hrustanovic, PhD,
  • John Maraganore, PhD,
  • Leigh Morgan,
  • Victor Sandor, MDCM,
  • Elena Ridloff, CFA,

Last updated: 2024-12-31

Pliant Therapeutics, Inc.

Pliant Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

PLN-74809

Pliant Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for the treatment of fibrosis and related diseases. Their lead product candidate, PLN-74809, is currently in Phase 2a trials.

Tags: biopharmaceutical, clinical trials, fibrosis, integrin inhibitor, therapies

Symbol: PLRX

Recent Price: $12.79

Industry: Biotechnology

CEO: Dr. Bernard Coulie M.B.A., M.D., Ph.D.

Sector: Healthcare

Employees: 166

Address: 260 Littlefield Avenue, South San Francisco, CA 94080

Phone: 650 481 6770

Last updated: 2024-12-31

Sutro Biopharma, Inc.

Sutro Biopharma, Inc. logo
Market Cap: Low
Employees: Low

Xpress CF+

Sutro Biopharma, Inc. operates as a clinical stage drug discovery, development, and manufacturing company, focusing on protein therapeutics for cancer and autoimmune disorders using their Xpress CF+ platform.

Tags: ADC, autoimmune disorders, biotechnology, cancer treatment, clinical trials, drug discovery

Symbol: STRO

Recent Price: $1.85

Industry: Biotechnology

CEO: Mr. William J. Newell J.D.

Sector: Healthcare

Employees: 304

Address: 111 Oyster Point Boulevard, South San Francisco, CA 94080

Phone: 650 881 6500

Leadership

  • John Doe, CEO
  • Jane Smith, CTO
  • Emily Johnson, Chief Financial Officer
  • Michael Brown, President
  • Linda Davis, Chairman
  • James Wilson, Founder

Last updated: 2024-12-31

TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

therapeutics for cancer

TRACON Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing cancer therapeutics, including clinical stage products like envafolimab, YH001, TRC102, and TJ004309, with collaboration agreements with various biopharmaceutical companies.

Tags: TJ004309, TRC102, YH001, biopharmaceutical, cancer therapeutics, clinical trials, envafolimab

Symbol: TCON

Recent Price: $0.03

Industry: Biotechnology

CEO: Mr. Craig R. Jalbert CIRA

Sector: Healthcare

Employees: 17

Address: 4350 La Jolla Village Drive, San Diego, CA 92122

Phone: 858 550 0780

Last updated: 2024-12-31

Finch Therapeutics Group, Inc.

Finch Therapeutics Group, Inc. logo
Market Cap: Lowest
Employees: Lowest

CP101

Finch Therapeutics Group, Inc. is a clinical-stage microbiome therapeutics company developing a novel class of orally administered biological drugs, with a lead candidate CP101 in Phase 3 trials for recurrent Clostridioides difficile infection, and a pipeline for other conditions.

Tags: biological drugs, biotechnology, clinical-stage, microbiome, therapeutics

Symbol: FNCH

Recent Price: $10.87

Industry: Biotechnology

CEO: Mr. Matthew P. Blischak J.D.

Sector: Healthcare

Employees: 1

Address: 200 Inner Belt Road, Somerville, MA 02143

Phone: 617 229 6499

Last updated: 2024-12-31